NCT05695183 is a NA clinical trial of IV SafeLock in Intravenous Access, sponsored by Mayo Clinic.

Who is sponsoring NCT05695183?

NCT05695183 is sponsored by Mayo Clinic.

What drugs are being tested in NCT05695183?

Interventions in NCT05695183: IV SafeLock.

What condition does NCT05695183 study?

NCT05695183 studies Intravenous Access.

Is NCT05695183 still recruiting?

NCT05695183 is currently completed. Last updated 10 October 2023.

Last reviewed 2023-10-10 · How we verify

NCT05695183

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

IV SafeLock Device Functionality in Emergency Department

Completed NA Last updated 10 October 2023

What this trial tests

NA trial testing IV SafeLock in Intravenous Access in 20 participants. Completed in 6 October 2023.

Timeline

22 July 2023

Primary endpoint
6 October 2023

6 October 2023

Quick facts

Lead sponsor	Mayo Clinic
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	device feasibility
Enrollment	20
Start date	22 July 2023
Primary completion	6 October 2023
Estimated completion	6 October 2023
Sites	1 location across United States

Drugs / interventions tested

IV SafeLock

Conditions studied

Intravenous Access — all drugs for Intravenous Access →

Sponsor

Mayo Clinic

Who can join

18 and older, any sex, with Intravenous Access. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research study is to evaluate the functionality of the IV SafeLock in the clinical emergency department setting.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Evaluation of the Functionality in an Emergency Department Setting of an Intravenous Protection Device to Prevent Self-Injection.
Bragg K, Albus M, Bragg B, Beste RM, et al · · 2024 · cited 3× · PMID 38529519 · DOI 10.2147/mder.s451439

Verify or expand the search:

Other Mayo Clinic trials

Trials by the same sponsor.

NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05695183 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
Last refreshed: 10 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05695183.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing